Discover the emerging class of degrader-antibody conjugates – a modality that is drawing increasing interest from biotech ...

GSK has finally called time on its pact with Mersana Therapeutics despite sinking $100 million to secure an option for an ...

Meanwhile, peroxisome proliferation-activated receptors (PPARs) are obesity drug targets in their own right: activating them can reduce inflammation and restore insulin sensitivity. But molecules that ...

Peptide Drug Conjugates (PDCs) present major growth opportunities in oncology and beyond, triggered by innovations in peptide chemistry, enhanced targeting, and reduced systemic toxicity. With a ...

Researchers tested the peptide BLMP6 in breast cancer models. The peptide demonstrated selective binding to metastatic cells ...

Five of seven serotypes in the pneumococcal conjugate vaccine, introduced for infants in the United States in 2000, are responsible for most penicillin-resistant infections. We examined the effect of ...

Patients with advanced platinum-resistant ovarian cancer whose disease had progressed on standard therapy experienced ...